The Board

Board members have a strong track record in corporate development including private and public capital raising, Initial Public Offer (IPO), and technology commercialisation.
 

Mr. Andrew Lord

BSc LL B

Non-Executive Director / Chairman

Andrew Lord was appointed Chairman of SDP Technology Limited in 2007. Andrew has practiced law for over 30 years specialising in the areas of venture capital private equity/debt, mezzanine funding, business structuring, corporations law and capital markets. In 2006 he was a founding partner in the boutique commercial law firm Lovegrove and Lord. He represents both biotechnology companies and venture capital funds, domestically and internationally. In addition to SDP Technology Limited, Andrew is actively involved at the board level with other unlisted and listed biotechnology companies. Currently, he is Company Secretary of Cordlife Limited; a health care company focused on umbilical cord blood banking. Andrew was involved with the listing of Cordlife on the ASX and its subsequent restructuring. He is Company Secretary of Cerylid Biosciences Limited; a biotechnology company focused on drug discovery and development. And in the lead up to and during the listing on the ASX, Andrew was Company Secretary of Cogstate Limited; a medical technology company focused on cognitive testing.
 

Mr. Ian Brown

MBA FAICD FAIM

Managing Director & CEO

Ian is the Managing Director and CEO of SDP Technology Ltd and the Managing Director of Avanti Capital. Ian is also a non executive director on a number of boards and has served as Chair and deputy Chair. Ian has lived and worked in Australia and Europe, and has worked on secondment on various projects in the United States and Asia. Prior to his current roles, Ian held senior executive positions with Chromogenix (previously Kabi Pharmacia) in Gothenburg Sweden, Instrumentation Laboratory in Milan Italy and several companies in Australia. In addition to his significant international corporate and business experience, Ian has led teams in M&A and JV transactions and post deal integration. His experience also covers start-ups, divestments and spin-outs, as well as private and public company capital raisings and IPO’s. Ian is a member of the Course Advisory Committee for the Masters of Entrepreneurship and Innovation Degree at the Australian Graduate School of Entrepreneurship (AGSE). Ian has an MBA and is a Fellow of both the Australian Institute of Company Directors and Australian Institute of Management, and is an alumnus of both INSEAD in France and MBS in Australia. 

Dr Steve Rietiker

MD

Non-Executive Director

Dr. Stephan Rietiker, is a Swiss citizen who qualified as a medical doctor at the Medical School of the University of Zurich and then spent 5 years in medical practice before moving into the Healthcare industry. He held various positions with increasing responsibility in marketing / general management with Roche, Boehringer Mannheim and Schering Plough before becoming Vice President and General Manager Europe for Covance Central Laboratory Services. In 2001, he was appointed President and CEO of Sulzer Medica (later Centerpulse) and was instrumental in resolving a landmark legal settlement in a major U.S. litigation as well as substantial business problems which threatened the existence of the company. Prior to taking on the role of Executive Director and CEO at IMI Intelligent Medical Implants in 2004, he was CEO and Director at the Swiss medical technology start-up company, Pendragon Medical AG. Since 2005 Dr. Rietiker has been a Senior Advisor of Brown Brothers Harriman's Corporate Finance Team. Moreover, he serves as Director of Contract Farming India AG and Inovio Biomedical Corporation. In 2007 he founded AurigaVision AG based in Zug, Switzerland, which serves as a platform with the ultimate goal to turn visions and technologies into successful businesses.
 

Mr. Alan Beasley

BEc CPA FCIS FAICD

Non-Executive Director

Alan Beasley has over 30 years experience in Investment Management. Alan commenced his career in 1975, as an Australian equities investment analyst and portfolio manager for institutional investors. Alan worked as an Associate Director with Bankers Trust (1980-1993), Director of Goldman Sachs Asset Management (1993-1995), Massachusetts Financial Services, (1995-1996), Managing Director and C.I.O., BNP Paribas Investment Management Australia (1996- 2002). Since 2002, Alan has worked as an Independent Investment Consultant and Company Director, and currently is Managing Director of Ascend Asset Management. Alan is also a member of the compliance committee of an ASX listed hedge fund; the listing appeals committee of the ASX, and a director of several unlisted public and private companies, including two charitable foundations.
 

Mr. Michael Derin

ACA ACIS ASIA BBus

Company Secretary
 
Michael Derin has over 13 years experience within the Chartered and Commercial sector. Michael has worked with companies such as PricewaterhouseCoopers, Compaq Financial Services and Oxley Corporate Group within a Financial Control/CFO capacity. Michael brings extensive understanding of complex tax issues in structured finance and corporate advisory and has helped partner many businesses in achieving growth through his solutions driven approach. Michael is an associate member of Institute of Chartered Accountants, FINSIA and Chartered Secretaries Australia.
 

Future Development

An essential element of the company's corporate development plan is to add strategically to the board and management as the company grows. The board intends to add strength and skills relating to biotechnology and/or pharmaceutical commercialisation during the course of the next 2 years.